C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $12 million versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.